We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current DMPHF market cap is 2.3B. The company's latest EPS is EUR and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 706.37M | 803.09M | 963.83M | 1.03B | 1.16B |
| Operating Income | 119.02M | 136.75M | 295.14M | 226.64M | 174.73M |
| Net Income | 77.2M | 85.83M | 208.23M | 134.24M | 62.37M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 1.04B | 1.22B | 1.41B | 1.41B | 2.16B |
| Total Liabilities | 760.38M | 899.81M | 907.14M | 880.35M | 1.62B |
| Total Equity | 284.49M | 324.58M | 499.83M | 532.49M | 545.05M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 100.61M | 131.1M | 250.37M | 288.53M | 219.42M |
| Investing | -382.15M | -105.91M | -129.35M | -99.01M | -415.43M |
| Financing | 183.96M | -14.09M | -80.98M | -199.77M | 204.54M |
| Market Cap | 2.3B |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 53.84M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 160.26 (99.99%) |
| Company Name | Dermapharm Holding SE (PK) |
| Address |
lil-dagover-ring 7 gruenwald 82031 |
| Website | https://www.dermapharm.de |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
